OPR - Delayed Quote • USD RPTX Jul 2024 7.500 call (RPTX240719C00007500) Follow 0.1500 0.0000 (0.00%) As of April 15 at 9:30 AM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for RPTX240719C00007500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: RPTX Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors Repare Therapeutics Inc.'s (NASDAQ:RPTX) market cap dropped US$21m last week; Private equity firms bore the brunt Repare Therapeutics Full Year 2023 Earnings: Misses Expectations Repare Therapeutics to Participate in Two Upcoming Investor Conferences Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023 Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release We're Keeping An Eye On Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Rate Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664 Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock? Repare Therapeutics to Regain Global Rights to Camonsertib Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
